WO2003082222A2 - Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides - Google Patents

Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides Download PDF

Info

Publication number
WO2003082222A2
WO2003082222A2 PCT/EP2003/002983 EP0302983W WO03082222A2 WO 2003082222 A2 WO2003082222 A2 WO 2003082222A2 EP 0302983 W EP0302983 W EP 0302983W WO 03082222 A2 WO03082222 A2 WO 03082222A2
Authority
WO
WIPO (PCT)
Prior art keywords
emulsifier
peg
polyethylene glycol
acid
oil
Prior art date
Application number
PCT/EP2003/002983
Other languages
German (de)
English (en)
Other versions
WO2003082222A3 (fr
Inventor
Jörg SCHREIBER
Mirko Tesch
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP03745267A priority Critical patent/EP1492490A2/fr
Publication of WO2003082222A2 publication Critical patent/WO2003082222A2/fr
Publication of WO2003082222A3 publication Critical patent/WO2003082222A3/fr
Priority to US10/953,586 priority patent/US20050124705A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/556—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14—Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations

Definitions

  • the present invention relates to low-viscosity, in particular sprayable O ⁇ / V emulsions containing phospholipids, processes for their preparation and their use for cosmetic or pharmaceutical purposes. They are used topically in particular, can serve as a wipe or tissue soaking medium, or can be sprayed or foamed.
  • Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are intended to protect against environmental influences, especially sun and wind, and to delay skin aging.
  • Medical compositions usually contain one or more drugs in effective concentration.
  • drugs for the sake of simplicity, reference is made to the legal provisions of the Federal Republic of Germany (e.g. cosmetics regulation, food and drug law) for a clear distinction between cosmetic and medical use and corresponding products.
  • Common manifestations of cosmetic or dermatological preparations are finely dispersed multiphase systems in which one or more fat or oil phases are present in addition to one or more water phases. Of these systems are as ⁇ derum the actual emulsions, the most widely used.
  • the present invention relates as special embodiments to cosmetic and dermatological light protection preparations, in particular to skin care cosmetic and dermatological light protection preparations.
  • UVG range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
  • UVA range It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can also cause damage. It has been shown that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it can be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
  • UV absorbers or UV reflectors are most inorganic pigments that are known to be used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications.
  • phospholipid-containing, low-viscosity O / W emulsions are also suitable for other cosmetic dermatological applications, for example deodorants, so that the present invention relates in a particular embodiment to phospholipid-containing, low-viscosity O / W emulsions as the basis for cosmetic deodorants.
  • Cosmetic deodorants are used to eliminate body odor that arises when the fresh, odorless sweat is decomposed by microorganisms.
  • the usual cosmetic deodorants are based on different active principles.
  • astringents predominantly aluminum salts such as aluminum hydroxychloride (aluminum chlorohydrate).
  • the use of antimicrobial substances in cosmetic deodorants can reduce the bacterial flora on the skin. Ideally, only the odor-causing microorganisms should be effectively reduced. The sweat flow itself is not affected by this, in the ideal case only the microbial decomposition of the sweat is temporarily stopped.
  • Deodorants should meet the following conditions: 1) They should cause reliable deodorization. 2) The natural biological processes of the skin must not be impaired by the deodorants.
  • liquid deodorants for example aerosol sprays, roll-ons and the like
  • solid preparations for example deodorant sticks, powders, powder sprays, intimate cleansers, etc.
  • lecithin-containing, low-viscosity O / W emulsions as a basis for deodorant or antiperspirant preparations is also known.
  • Their relatively high content of emulsifiers, with the disadvantages described, was previously a problem that had to be remedied. It was therefore a further object of the present invention, ⁇ wrap preparations to ent, which are suitable as a basis for cosmetic deodorants and antiperspirants, and not have the disadvantages of the prior art.
  • a further object of the present invention was to provide products based on lecithin-containing, low-viscosity O / W emulsions with the widest possible range of applications.
  • preparation forms such as cleaning emulsions, face and body care preparations, but also very medicinal-pharmaceutical forms of administration should be created, for example preparations for acne and other skin symptoms.
  • the invention therefore relates to cleaning emulsions, in particular facial cleaning emulsions, preferably make-up removers, for example eye make-up removers.
  • Such preparations are known per se. These are usually mixtures of cosmetic oils or aqueous preparations of surface-active substances, the function of which is to solubilize the impurity or the make-up body and to remove it from the skin.
  • Waterproof eye make-up for example mascara
  • make-up removers on an aqueous basis using special surfactants.
  • these aspects often have only limited physiological tolerance.
  • these substances come into contact with the mucous membrane, in particular the mucous membrane of the eyes, these substances cause irritation, which is manifested, for example, in reddening of the eyes. Reactions of this kind are typical for products containing surfactants.
  • the present invention relates to hair cosmetic preparations.
  • the present invention relates to hair cosmetic preparations for the care of the hair and the scalp.
  • the present invention relates to preparations which serve to strengthen the individual hair and / or to give the hair style overall hold and fullness.
  • human hair can be divided into the living part, the hair root, and the dead part, the hair shaft.
  • the hair shaft in turn consists of the medulla, which, due to developmental history, has become insignificant and receded for modern humans and is often completely absent with thin hair, furthermore the cortex surrounding the medulla and the cuticle surrounding the whole of the medulla and cortex.
  • the cuticle in particular, but also the keratinous area between the cuticle and cortex as the outer covering of the hair, are particularly exposed to environmental influences, by combing and brushing, but also by hair treatment, in particular hair coloring and hair shaping, e.g. Perm method, exposed.
  • the interior of the hair can also be affected.
  • oxidants such as hydrogen peroxide
  • the dye chromophore is formed by the reaction of precursors (phenols, aminophenols, less often diamines) and bases (mostly p-phenylenediamine) with the oxidizing agent, mostly hydrogen peroxide. Hydrogen peroxide concentrations around 6% are usually used.
  • the hydrogen peroxide also has a bleaching effect. Similar to bleached hair, microscopic holes in the areas where melanin granules were present can be detected in oxidatively colored human hair. The fact is that the oxidizing agent hydrogen peroxide not only with the color precursors, but also with the Hair substance react and may cause damage to the hair.
  • washing hair with aggressive surfactants can stress the hair, at least reduce its appearance or the appearance of the hairstyle overall.
  • certain water-soluble hair components e.g. urea, uric acid, xanthine, keratin, glycogen, citric acid, lactic acid
  • hair care cosmetics have been used for some time, which are intended to be rinsed out of the hair again after exposure, and others which are intended to remain on the hair.
  • the latter can be formulated in such a way that they not only serve to care for the individual hair, but also improve the overall appearance of the hairstyle, for example by giving the hair more volume, fixing the hairstyle over a longer period of time or improving its manageability.
  • the combability of the hair can be decisively improved by quaternary ammonium compounds. Such connections are drawn onto the hair and are often still detectable on the hair after several washes.
  • a particular object of the present invention was to provide finely dispersed oil-in-water preparations with the lowest possible emulsifier content, which do not have the disadvantages of the prior art and which are suitable for a wide variety of cosmetic and / or dermatological applications, for example, can find the uses described above.
  • Another object of the invention was to enrich the limited supply of finely dispersed oil-in-water preparations of the prior art.
  • a particular object of the present invention was to provide low-viscosity preparations based on finely dispersed oil-in-water systems with the lowest possible emulsifier content, which do not have the disadvantages of the prior art and which are suitable for a wide variety of cosmetic and / or dermatological Applications, for example the uses described above can find.
  • Another object of the invention was to enrich the limited range of low-viscosity preparations based on finely dispersed phospholipid-containing systems of the oil-in-water type of the prior art.
  • a further object of the invention was to enrich the limited supply of low-viscosity preparations based on finely dispersed phospholipid-containing systems of the oil-in-water type of the prior art, which can be sprayed or can also serve as impregnation medium for wipes, tissues or from one Pumpoamer can be used as foam.
  • Lecithin-containing emulsions for cosmetic, pharmaceutical, parenteral applications are known from the literature. These are often obtained by high pressure homogenization. It is disadvantageous that high shear forces arise on the droplets and metal abrasion occurs which can only be removed with difficulty from the corresponding dosage forms. Ultrasound can also be used to produce emulsions. The disadvantage is that these methods are expensive because of the high energy input. High pressure homogenization or ultrasound for the production of parenteral emulsions for cosmetic or pharmaceutical applications are described in the literature. Int. J. Pharm. 163, 1998, 81; J. Pharm. Belg. 52, 1997, 110; J. Pharm. 82, 1993, 1069; J. Pharm. 83, 1994, 72; Pari and cosmetics. 10, 1994, 652; 3, 1995, 152; Pharm. Res. 12, 1995, 1273; S ⁇ FW 9, 1994, 530.
  • EP 406162 B1 describes a method for producing a nanoemulsion with triglycerides or fatty acid esters.
  • the emulsifier lecithin should have a lamellar liquid-crystalline structure, which is then processed with a high-pressure homogenizer to form the nanoemulsion.
  • DE 3930928 C2 describes pharmaceutical formulations containing cyclosporin based on a microemulsion.
  • propylene glycol or glycofurol is advantageously used as the hydrophilic component as the microemulsion concentrate.
  • these concentrates represent O / W or W / O macroemulsions.
  • the gel state which can advantageously be run through, which is not to be regarded as a macroemulsion, or the final formation of low-viscosity, lecithin-containing emulsions is not mentioned.
  • short-chain ethers such as Transcutol and Glycofurol are not very suitable for cosmetic purposes due to their penetration.
  • DE 3302898 describes lecithin-containing systems containing fatty acids and protein condensates from a fatty acid, ethoxylated sterols. The choice of ingredients and the manufacturing process can only be used to a limited extent.
  • DE 4410710 describes emulsions with lecithin and a hydrophobic co-emulsifier (W / O emulsifier). Low-viscosity (sprayable) emulsions containing O / W emulsifiers, W / O emulsifiers and phospholipids have not been described as advantageous.
  • DE 3129340 describes emulsions with lecithin and saponoside as emulsifiers, which are further stabilized by aloe juice. A generally applicable process without these substances is not described.
  • WO 0037042 describes a method for producing low-viscosity transparent lecithin-containing microemulsions. A process for the preparation of sprayable emulsions is not described.
  • Lecithin organogels are described in the literature. Colloid Polymer Science 268,
  • organogels are obtained by adding small amounts of water to a mixture of organic solvent and lecithin. Thereby arise from inverse
  • mice when water is added, cylinder-like water-filled micelles ("wormlike micelles") that loop together and thus explain the high viscosity of these mixtures. (Colloid Polym. Sci. 268, 1990, 356).
  • these lecithin gels are not microemulsion gels, since the dispersed phase is not in droplet form and, furthermore, there is no corresponding viscosity-increasing substance for the continuous phase. Furthermore, it is not described that these gels can also be obtained in the presence of an O / W emulsifier.
  • Preparations can be obtained which can be converted into low-viscosity, phospholipid-containing O / W emulsions by dilution with water.
  • the object of the invention was to avoid the disadvantages mentioned.
  • the invention relates to a process for the preparation of low-viscosity, in particular sprayable, phospholipid-containing emulsions of the oil-in-water type, comprising a water phase and an oil phase, which are composed essentially of non-volatile constituents, containing at least one
  • Phospholipid and at least one oil-in-water emulsifier and optionally at least one W / O emulsifier can be obtained in such a way that part of the water phase with its constituents is added to the
  • Emulsifier and optionally the W / O emulsifier is added, the phases being mixed with one another and a gel state being obtained which is characterized by further
  • Addition of the water phase is converted into a low-viscosity O / W emulsion, where the phases may contain further auxiliaries, additives and / or active ingredients if desired.
  • the water phase is expediently metered or added dropwise to the oil phase until there is an increase in viscosity or a gel is formed, and the remaining water phase is then metered in.
  • the phospholipid is advantageously dissolved in the oil phase (possibly in the heat). However, it is also possible to dissolve the phospholipid in the oil at room temperature.
  • the O / W emulsifier can be added directly to the oil phase or only at the stage of gel formation or after production of the "pure" phospholipid organogel.
  • the water phase can be added at room temperature or at elevated temperature.
  • the droplet diameters of the preparations according to the invention are preferably in the ranges mentioned at the beginning.
  • “Leeithine” here also means the phospholipids, which include, for example, the following substances: phosphatidic acids, the actual Leeithine, cardolipins, lysophospholipids, lysolecithins, plasmalogens, phosphosphingolipids, sphingomyeline. Preferred substances are described below.
  • Phosphatidic acids are glycerol derivatives which are esterified in the 1-sn and 2-position with fatty acids (1-sn position: mostly saturated, 2-position: mostly mono- or polyunsaturated), on the other hand at atom 3-sn with phosphoric acid and by the general structural formula
  • Leeithine 3-sn-phosphatidylcholine
  • choline 3-sn-phosphatidylcholine
  • 2-aminoethanol ethanolamine
  • L-serine laminoethanol
  • cephalin 3-sn-phosphatidylethanolamine or sn -Phosphatidyl-L-serine
  • R and R 2 typically unbranched aliphatic radicals having 15 or 17 carbon atoms and up to 4 cis double bonds represent.
  • Cardiolipins (1,3-bisphosphatidylglycerols) are phospholipids made from two phosphatidic acids linked via glycerol.
  • Lysophospholipids are obtained when an acyl residue is split off from phospholipids by phospholipase A (e.g. lysolecithins).
  • phospholipase A e.g. lysolecithins
  • Lysolecithins for example, are characterized by the general structural formula
  • R and R 2 are typically unbranched aliphatic radicals having 15 or 17 carbon atoms and up to 4 cis double bonds.
  • the phospholipids also include plasmalogens in which an aldehyde (in the form of an enol ether) is bound in the 1 position instead of a fatty acid; the O-1-sn-alkenyl verb corresponding to the phosphatidylcholines. z. B. are called phosphatidal cholines.
  • the basic structure of the phosphosphingolipids is based on sphingosine or phytosphingosin, which are characterized by the following structural formulas: CH 2 OH CH 2 OH
  • R ⁇ and R 3 independently of one another represent saturated or unsaturated, branched or unbranched alkyl radicals of 1 to 28 carbon atoms
  • R 2 is selected from the group: hydrogen atom, saturated or unsaturated, branched or unbranched alkyl radicals of 1 to 28 carbon atoms, sugar residues, phosphate groups esterified or unesterified with organic radicals, sulfate groups esterified or unesterified with organic radicals and Y represents either a hydrogen atom, a hydroxyl group or another heterofunctional radical.
  • RT and R 3 represent alkyl radicals
  • R 4 represents an organyl radical
  • Sphingomyeline are organylphosphorylated sphingolipids of the type
  • Lecithin types to be used advantageously are selected from crude lecithins which have been deoiled and / or fractionated and / or spray dried and / or acetylated and / or hydrolyzed and / or hydrogenated. They are commercially available. Soy lecithins are preferred.
  • Phospholipids to be used advantageously according to the invention can be purchased, for example, under the trade names Phospholipon 25 or Phospholipon 90 (Nattermann), Emulmetik 120 (Lucas Meyer), Sternpur E (Stern), Sternpur P (Stern), Nathin 3KE (Stern), Phospholipon 90 H (Nattermann / Rhone-Poulenc), Lipoid S 100 (Lipoid).
  • novel gels in which other colloid chemical phases are also present, can arise than in the "pure" lecithin organogels known in the literature, such as lamellar liquid crystals, cubic phases , bicontinuous microemulsion gels, O / W microemulsion gels, inverse hexagonal phases, hexagonal phases, inversely micellar phases.
  • the intermediate gel formation according to the invention i.e. the corresponding colloid chemical phase
  • its targeted degradation by dilution with water i.e. the conversion of the colloid chemical phase into another
  • This makes it possible for the first time to use a large number of O ⁇ V emulsifiers and W / O emulsifiers.
  • the greater variability in the choice of O / W emulsifiers and W / O emulsifiers favors a greater variety of cosmetic oil phases.
  • the intermediate gel formation results in hydrophilic, lipophilic and surface-active domains within the gel, so that active substances of different polarities can be solubilized much more easily in parallel, since the active substances voluntarily dissolve in the corresponding domain in accordance with their hydrophilicity / lipophilicity.
  • additives for the oil phase 0.01-15% additives for the water phase: 0.01-35% water * ad 100%
  • the weight ratio of phospholipid / (O / W emulsifier / W / O emulsifier) in the preparations according to the invention can vary, for example from 1:30 to 2: 1.
  • the ratio of phospholipid / OW emulsifier is preferably 1:15 to 1: 1.
  • the ratio of phospholipid / OW emulsifier is particularly preferably 1: 6 to 1: 1, 3.
  • the ratio of (phospholipid + W / 0 emulsifier) to O / W emulsifier can vary, for example 1:30 to 2: 1, the ratio (phospholipid + W / O emulsifier) to O / W emulsifier is preferably 1: 6 to 1: 1, 3.
  • emulsions of the oil-in-water type which comprise a discontinuous oil phase and a continuous water phase, optionally containing at least one W / O emulsifier - containing at least one phospholipid and containing at least one Q / W emulsifier the O / W emulsifier (s) is advantageously chosen or are selected from the group of fatty alcohol ethoxylates of the general formula R- ⁇ - (- CH 2 -CH 2 -O-) n -H, where R is a branched or unbranched alkyl, aryl - or
  • Alkenyl radical and n represent a number from 10 to 50 of the ethoxylated wool wax alcohols, the polyethylene glycol ether of the general formula RO - (- CH 2 -CH 2 -O-) n -R ', where R and R' independently of one another are branched or unbranched alkyl or Alkenyl radicals and n represent a number from 10 to 80 of the fatty acid ethoxylates of the general formula
  • R-COO - (- CH 2 -CH 2 -0-) n -H where R is a branched or unbranched alkyl or alkenyl radical and n is a number from 10 to 40, of the etherified fatty acid ethoxylates of the general formula R-COO- ( -CH 2 -CH 2 -0-) n -R ', where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals and n is a number from 10 to 80, of the esterified fatty acid ethoxylates of the general formula R-COO- ( -CH 2 -CH 2 -0-) n -C (0) -R ', where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals and n is a number of
  • 10 to 80 represent the polyethylene glycol glycerol fatty acid ester of saturated and / or unsaturated, branched and / or unbranched fatty acids and a degree of ethoxylation between 3 and 50, - of the ethoxylated sorbitan esters with a degree of ethoxylation of 3 to 100 the cholesterol ethoxylates with a degree of ethoxylation between 3 and 50, the ethoxylated triglycerides with a degree of ethoxylation between 3 and 150, the alkyl ether carboxylic acids of the general formula RO - (- CH 2 -CH 2 -O-) n -CH 2 -C0OH or their cosmetic or pharmaceutically acceptable salts, where R is a branched or unbranched alkyl or alkenyl radical having 5 to 30 carbon atoms and n is a number from 5 to 30, the polyoxyethylene sorbitol fatty acid ester based on branched or unbranched al
  • alkyl ether carboxylic acids of the general formula RO - (- CH 2 -CH (CH 3 ) O-) n -CH 2 -COOH or their cosmetically or pharmaceutically acceptable salts, where R is a branched or unbranched alkyl or alkenyl radical and n represent a number from 3 to 50, the alkyl ether sulfates or the acids on which these sulfates are based, of the general formula RO - (- CH 2 -CH (CH 3 ) -O-) n -SO 3 -H with cosmetically or pharmaceutically acceptable cations, where R is a branched or unbranched alkyl or alkenyl radical having 5 to 30 carbon atoms and n is a number from 1 to 50, the fatty alcohol ethoxylates / propoxylates of the general formula RO-Xn-Ym-H, where R is a branched or unbranched alkyl or Represent alkenyl radical, where R is
  • 100 represent the etherified fatty acid propoxylates of the general formula R-COO-Xn-Ym-R ', where R and R' independently represent branched or unbranched alkyl or alkenyl radicals, where X and Y are not identical and each have either an oxyethylene group or one oxy propylene group and n and m independently of one another represent numbers from 5 to 100, the fatty acid ethoxylates / propoxylates of the general formula R-COO-X n -Y m -H, where R is a branched or unbranched alkyl or alkenyl radical, where X and Y are not identical are and each represent either an oxyethylene group or an oxypropylene group and n and m independently of one another are numbers from 5 to 50, the polyglycerol methyl glucose ester of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids or
  • this W / O emulsifier being selected from the group of
  • fatty alcohol ethoxylates of the general formula R-0 - (- CH 2 -CH 2 -0-) n -H, where R is a branched or unbranched alkyl, aryl or alkenyl radical and ⁇ is a number from 1 to 10
  • polyethylene glycol ether of the general formula R-0 - (- CH 2 -CH 2 -0-) n -R ', where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals and n is a number from 1 to 30
  • R-COO - (- CH 2 -CH 2 -0-) n -H where R is a branched or unbranched alkyl or alkenyl radical and n is a number from 1 to 20,
  • esterified fatty acid ethoxylates of the general formula where R and R 'are independent of each other branched or unbranched alkyl or alkenyl radicals and n represent a number from 1 to 20,
  • R and R 'independently of one another are branched or unbranched alkyl or alkenyl radicals and n is a number from 1 to 40 of the fatty alcohol propoxylates of the general formula R-0 - (- CH 2 -CH (CH 3 ) -0-) ⁇ -H, where R is a branched or unbranched alkyl or alkenyl radical and n is a number from 1 to 30,
  • polyoxyethylene sorbitan fatty acid ester based on branched or unbranched alkanoic or alkenoic acids and having a degree of ethoxylation of 1 to 10
  • cholesterol ethoxylates with a degree of ethoxylation between 1 and 10,
  • polyglycerol mono- or di- or polyester where the fatty acids independently of one another represent branched or unbranched alkyl, hydroxyalkyl or alkenyl radicals,
  • the pentaerythritol ester the fatty acids independently of one another being branched or unbranched alkyl, hydroxyalkyl or alkenyl radicals,
  • the propylene glycol ester the fatty acids independently of one another being branched or unbranched alkyl, hydroxyalkyl or alkenyl residues,
  • the sorbitan ester where the fatty acids independently of one another represent branched or unbranched alkyl, hydroxyalkyl or alkenyl residues,
  • fatty alcohols R-OH and fatty acids RCOOH where R represents a branched or unbranched alkyl or alkenyl radical
  • the silicone emulsifiers such as dimethicone copolyol, alkyl dimethicone copolyol (cetyl dimethicone copolyol), alkyl methicone copolyols, (lauryl methicon copolyol), octyl dimethicone ethoxy glucosides of methyl glucose esters, the fatty acids independently representing branched or unbranched alkyl, hydroxyalkyl or alkenyl radicals.
  • the total emulsifier content is preferably 0.01 to 20% by weight, based on the total weight of the preparation. It is particularly advantageous if the O / W emulsifier or the O / W emulsifiers are selected or are selected from the group of fatty alcohol ethoxylates of the general formula R-0 - (- CH 2 -CH 2 -0-) n -H, where R is a branched or unbranched alkyl or alkenyl radical with 5-30 C
  • Atoms and n represent a number from 10 to 25 of the ethoxylated wool wax alcohols with HLB values of 11-16 of the polyethylene glycol ethers of the general formula R-0 - (- CH 2 -CH 2 -0-) ⁇ -R ', where R and R 'are independently branched or unbranched alkyl or alkenyl radicals having 5 to 30 carbon atoms and n are a number from 10 to 25, the fatty acid ethoxylates of the general formula R-COO - (- CH 2 -CH 2 -0-) n -H , where R is a branched or unbranched alkyl or alkenyl radical having 5 to 30 carbon atoms and n is a number from 10 to 25, of the etherified fatty acid ethoxylates of the general formula R-COO - (- CH 2 -CH 2 -0-) n -R ', where R and R' independently of one another are branched or unbranched
  • Alkenyl radical with 5 to 30 carbon atoms and n represent a number from 10 to 20, the polyoxyethylene sorbitol fatty acid ester based on branched or unbranched alkanoic or alkenic acids and having a degree of ethoxylation of 10 to 80, for example of the sorbeth type, of the alkyl ether sulfates or the acids of these sulfates on which all general formula RO - (- CH 2 -CH 2 -O-) n -SO 3 -H with cosmetically or pharmaceutically acceptable cations, where R is a branched or unbranched alkyl or alkenyl radical having 5 to 30 carbon atoms and n is a number of 3 to 30 represent the fatty alcohol propoxylates of the general formula
  • RO - (- CH 2 -CH (CH 3 ) -0-) n -R ' where R and R' independently of one another are branched or unbranched alkyl or alkenyl radicals having 5 to 30 carbon atoms and n is a number from 10 to 40 represent the propoxylated wool wax alcohols with HLB values of 1 1 - 16, - of the fatty acid propoxylates of the general formula
  • the polyethoxylated and / or polypropoxylated O / W emulsifiers used are particularly advantageously selected from the group of substances with HLB values of 1-16.
  • fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetylstearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Iso-laureth-12).
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / caprinate 20, polyethylene glycol glyceryl oleate, polyethylene glycol (20) glyceryl iso stearate, polyethylene glycol (18) glyceryl oleate / cocoat to choose.
  • sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • Abil Care 85 can be selected as the silicone emulsifier.
  • W / O emulsifiers can be used: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids or hydroxyalkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C- Atoms, diglycerol esters saturated and / or unsaturated, branched and / or un branched alkane carboxylic acids or hydroxyalkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 carbon atoms, diglycerol ether saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 carbon atoms, diglycerol ether
  • W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl linoleate, triglycerol diisostearate, glyceryl monomyristate,
  • Glyceryl mono-oleate diglyceryl monostearate, diglyceryl monoisostearate
  • Glyceryl monocaprinate glyceryl monocaprylate, polyglyceryl-3 methylglucose distearate,
  • Sorbitan perisostearate PEG-30 dipolyhydroxystearate.
  • the total emulsifier content less than 15% by weight, based on the total weight of the preparations according to the invention. It is preferred to keep the total content of emulsifiers less than 10% by weight, in particular less than 8% by weight, based on the total weight of the preparations.
  • Glycerol, chitosan, Fucpgel, 2-methyl-propanidol, lactic acid, propylene glycol, dipropylene glycol, butylene glycol, mannitol, polyethylene glycol, acids and their salts such as sodium pyrolidonecarboxylic acid, glycine can advantageously be used as skin moisturizers.
  • Glycerin alone and in combination with one of the previously mentioned moisturizers is particularly advantageous.
  • skin-moistening ingredients containing phospholipid-containing, low-viscosity (sprayable) O / W emulsions have excellent properties for moisturizing, smoothing and reducing the flaky skin.
  • Ethoxylated fatty acid esters and fatty acid glycerides in particular PEG-50 hydrogenated castor oil isostearate PEG-45 palm kernel oil glycerides
  • Ethoxylated sorbitan esters especially PEG-20 sorbitan isostearate PEG-20 sorbitan monooleate
  • Polyglycerol esters especially polyglycerol-10 stearate, polyglycerol-10 laurate
  • Ethoxylated glycerol esters in particular PEG-20 glyceryl laurate PEG-20 glyceryl steart
  • Fatty acid ethoxylates in particular PEG-20 monostearate
  • the oil phase of the preparations according to the invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length from 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, iso-octyl stearate, isononyl stearate, isononylisono ⁇ anoate, 2-ethyl-2-ethylhexyl, ethyl-2-ethylhexyl-2-ethylhexyl Hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate as well as synthetic, semi-synthetic and natural mixtures of such esters, for example jojoba oil.
  • the oil phase can advantageously be chosen from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • Examples of advantageous are dicaprylyl carbonate, butylene glycol caprylate / caprate, di- C12-13 alkyl tartrate, caprylic / capric diglyceryl succinate, caprylic / capric triglyceride, octyldodecanol, cetearyl isonoanoate, cocoglyceride, mineral oil, hydrogenated, iso-cyclo-hexane, polydecylanocanoate, polydecylane squalene, C 12 . ⁇ 5 alkyl benzoate and mixtures of these oil phases.
  • waxes can also be part of the oil phase, such as, for example, methyl palmitate, cetyl palmitate, Ca o-alkyl stearate, C 18-3 6-acid triglyceride.
  • the preparations according to the invention may also be obtained as micro-dispersions of solid wax particles. Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Phospholipid 0.01-10%, especially 0.1-5.0%
  • O / W emulsifier 0.01-60%, in particular 0.1-10%
  • W / O emulsifier 0.01-60%, especially 0.1-10%
  • Oil phase 0.01 - 50%, especially 0.1 - 30%
  • additives for the oil phase 0.01-20%, especially 0.1-15% additives for the water phase: 0.01-80%, especially 0.1-60%
  • the weight ratio phospholipid / (O / W emulsifier / W / O emulsifier) in the preparations according to the invention can vary, e.g. from 1:30 to 2: 1.
  • the ratio of phospholipid / OW emulsifier is preferably 1:15 to 1: 1.
  • the ratio of phospholipid / OW emulsifier is particularly preferably 1: 6 to 1: 1, 3.
  • the ratio of (phospholipid + W / O emulsifier) to O / W emulsifier can vary, for example 1:30 to 2: 1, the ratio (phospholipid + W / O emulsifier) to O / W emulsifier is 1: 6 to 1: 1, 3.
  • microemulsion gels according to the invention advantageously contain electrolytes, in particular one or more salts with the following anions: chlorides, furthermore inorganic oxo-element anions, of which in particular sulfates, carbonates, phosphates, borates and aluminates.
  • Electrolytes based on organic anions can also be used advantageously, for example lactates, acetates, benzoates, propionates, Tartrate, Citrate and others. Comparable effects can also be achieved with ethylenediaminetetraacetic acid and its salts.
  • Ammonium, alkylammonium, alkali metal, alkaline earth metal, magnesium, iron and zinc ions are preferably used as cations of the salts.
  • electrolytes there is no need to mention that only physiologically acceptable electrolytes should be used in cosmetics.
  • special medical applications of the microemulsions according to the invention can, at least in principle, require the use of electrolytes, which should not be used without medical supervision.
  • Sodium and potassium chloride, sodium and potassium bromide, magnesium and calcium chloride, magnesium and calcium bromide, zinc sulfate and mixtures thereof are particularly preferred. Salt mixtures as they occur in the natural salt from the Dead Sea are also advantageous. All of these salts are beneficial because they stimulate endogenous lipid synthesis.
  • the concentration of the electrolyte or electrolytes should be, for example, approximately 0.1-10.0% by weight, particularly advantageously approximately 0.3-8.0% by weight, based on the total weight of the preparation.
  • the preparations described below can be phospholipid-containing, low-viscosity (sprayable) O / W emulsions according to the invention.
  • odor maskers such as the common perfume components
  • odor absorbers for example the layered silicates described in patent application DE-P 40 09 347, of which montmorillonite in particular , Kaolinite, llite, beidellite, nontronite, saponite, hectorite, bentonite, smectite, and furthermore, for example, zinc salts of ricinoleic acid.
  • Germ-inhibiting agents are also suitable for being incorporated into the microemulsions according to the invention.
  • Advantageous substances are, for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (irgasane), 1,6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, quaternary ammonium compounds, clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3.7.1 LTrimethyl 2,6,10-dodecatrien-1-ol) and those described in patent publications DE-37 40 186, DE-39 38 140, DE-42 04 321, DE-42 29 707, DE-42 29 737, DE-42 37 081, DE-43 09 372, DE-43 24 219 described effective agents.
  • irgasane 1,6-di- (4-chlorophenylbiguanido) hexane
  • chlorhexidine 1,6-di- (4-chlorophenylbiguanido)
  • customary antiperspirant active ingredients can likewise advantageously be used in the phospholipid-containing, low-viscosity O / W emulsions according to the invention, in particular astringents, for example basic aluminum chlorides.
  • the cosmetic deodorants according to the invention can be in the form of aerosols, that is to say from aerosol containers, squeeze bottles or preparations sprayable by a pump device, or in the form of liquid compositions which can be applied by means of roil-on devices, but also in the form of low-viscosity phospholipid-containing substances which can be applied from normal bottles and containers O / W emulsions.
  • Suitable blowing agents for cosmetic deodorants according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • the preparations according to the invention are sprayed as aerosol droplets.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • these preferably additionally contain at least one UVA filter substance and / or at least one UVB filter substance and / or at least one inorganic pigment.
  • UV-A or UV-B filter substances are usually incorporated into day creams.
  • Preparations according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 9% by weight, based on the total weight of the preparations, for cosmetic and / or dermatological purposes To provide preparations that protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
  • Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (Ti0 2 ), zinc (ZnO), iron (e.g. Fe 2 O 3 ), zirconium (ZrO 2 ), silicon ( Siö 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
  • such pigments can advantageously be superficial treated ("coated"), whereby, for example, an amphiphilic or hydrophobic character is to be formed or retained.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
  • z. B titanium dioxide pigments coated with octylsilanol. Suitable titanium dioxide particles are available under the trade name T805 from Degussa. Also particularly advantageous are Ti0 2 pigments coated with aluminum stearate, e.g. B. those available under the trade name MT 100 T from TAYCA.
  • Another advantageous coating of the inorganic pigments consists of dimethylpolysiloxane (also: dimethicone), a mixture of fully methylated, linear siloxane polymers which are blocked at the end with trimethylsiloxy units.
  • Zinc oxide pigments which are coated in this way are particularly advantageous for the purposes of the present invention.
  • the inorganic pigments are also advantageous to coat with a mixture of dimethylpolysiloxane, in particular dimethylpolysiloxane with an average chain length of 200 to 350 dimethylsiloxane units, and silica gel, which is also referred to as simethicone. It is particularly advantageous if the inorganic pigments are additionally coated with aluminum hydroxide or aluminum oxide hydrate (also: alumina, CAS no .: 1333-84-2). Titanium dioxides coated with simethicone and alumina are particularly advantageous, the coating also being able to contain water. An example of this is the titanium dioxide available from Merck under the trade name Eusolex T2000.
  • An advantageous organic pigment for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCI : Bis-octyltriazole], which is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.
  • UV-A filter substances in the sense of the present invention are di-benzoylmethane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the brand Parsol ® 1789 and before Merck under the trade name Eusolex® 9020.
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives. Particularly preferred are the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: Aniso triazine ), which is available under the trade name Tinosorb® S from CIBA-Chemicals GmbH.
  • Particularly advantageous preparations within the meaning of the present invention which are distinguished by a high or very high UV-A protection, preferably contain a plurality of UV-A and / or broadband filters, in particular dibenzoylmethane derivatives [for example 4- (tert-butyl) -4'-methoxydibenzoylmethane], benzotriazole derivatives [e.g.
  • UV filter substances which the structural motif
  • R represents a branched or unbranched CrC ⁇ alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted with one or more dC 4 alkyl groups
  • X represents an oxygen atom or an NH group
  • Ri represents a branched or unbranched C ⁇ -C 18 alkyl, a C 5 -C 12 cycloalkyl, optionally substituted with one or more dC- 4 - alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 8 -alkyl radical, a C 5 -C 12 -cycloalkyl or aryl radical, optionally substituted by one or more C ! -C 4 - alkyl groups,
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10
  • R 2 represents a branched or unbranched C 1 -C 18 -alkyl radical, a C -C 2 -cycloalkyl radical, optionally substituted with one or more Ci-Ci - 1 represents alkyl groups when X represents the NH group, and a branched or unbranched CrC ⁇ alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A is a branched or unbranched d-cis-alkyl radical, a C 5 -C 12 -
  • a particularly preferred UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon (INCI: dioctylbutamidotriazone) and under the trade name UVA SORB HEB is available from Sigma 3V.
  • s-triazine 4,4, 4 "- (1, 3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2- ethylhexyl ester), synonymous: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: octyl triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
  • European laid-open specification 775 698 also describes bis-resorcinyltriazine derivatives which are preferably to be used and whose chemical structure is represented by the generic formula
  • R, R 2 and A ⁇ represent a wide variety of organic radicals.
  • Also advantageous in the sense of the present invention are the 2,4-bis - ⁇ [4- (3-sulfonotone) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) - 1,3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl ) -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethyl carboxyl) - phenylamino] -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- [
  • An advantageous broadband filter in the sense of the present invention is the 2,2'-Me ethylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1, 1, 3,3-tetramethylbutyl) phenol), which is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyfpropylj-phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane.
  • the UV-B and / or broadband filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B and / or broadband filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
  • Advantageous water-soluble UV-B and / or broadband filter substances are e.g. For example: “Salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
  • ⁇ sulfonic acid derivatives of 3-benzylidene camphor such as.
  • Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and its salts especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI- Name Bisimidazylate (CAS No .: 180898-37-7), which, for example, under the trade name Neo
  • UV-A filter substances are the phenylene-1,4-bis (2-benzimizazyl) -3,3'-5,5'-tetrasulfonic acid and its salts, especially the corresponding sodium, potassium or Triethanolammonium salts, especially the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI-
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS no .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is available under the trade name Mexoryl® XL from Chimex.
  • a further light protection filter substance erfindcingsloom to be used advantageously is ethylhexyl-2-cyano-3,3-diphenylacrylate, obtainable (octocrylene) from BASF under the name Uvinul ® N 539th
  • film formers may also be advantageous to incorporate film formers into the cosmetic or dermatological preparations according to the invention, for example in order to improve the water resistance of the preparations or to increase the UV protection performance (UV-A and / or UV-B boosting).
  • Both water-soluble or dispersible and fat-soluble film formers are suitable, in each case individually or in combination with one another.
  • Advantageous fat-soluble film formers are e.g. B., the film formers from the group of polymers based on polyvinylpyrrolidone (PVP)
  • copolymers of polyvinylpyrrolidone for example the PVP hexadecene copolymer and the PVP eicosen copolymer, which are available under the trade names Antaron V216 and Antaron V220 from the GAF Chemicals Cooperation, as well as the Tricontayl PVP and the like.
  • Cosmetic and / or dermatological preparations according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of Titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. The amounts given for the above combinations can be used.
  • preparations according to the invention are very good vehicles for cosmetic or dermatological active ingredients in the skin, advantageous active ingredients being antioxidants which can protect the skin against oxidative stress.
  • the preparations advantageously contain one or more antioxidants. All of the antioxidants suitable or customary for cosmetic and / or dermatological applications are used as inexpensive, but nevertheless optional antioxidants. It is advantageous to use antioxidants as the only class of active ingredient, for example when cosmetic or dermatological application is in the foreground, such as combating the oxidative stress on the skin. However, it is also advantageous to provide the preparations according to the invention with one or more antioxidants if the preparations are to serve another purpose, e.g. as deodorants or sunscreens.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg ⁇ -carotene, ß-carotene, Lycopi ⁇ ) and their derivatives, lipoic acid and their derivatives (eg dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cy - stone, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl
  • buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, himinath
  • low tolerable dosages e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -Hy droxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ⁇ -linolenic acid Linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg - ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g.
  • vitamin E acetate
  • vitamin A and derivatives Vitamin A - palmitate
  • Water-soluble antioxidants can be used particularly advantageously for the purposes of the present invention.
  • compositions according to the invention are very good vehicles for cosmetic or dermatological active ingredients in the skin, preferred active ingredients being antioxidants which can protect the skin against oxidative stress.
  • preferred active ingredients being antioxidants which can protect the skin against oxidative stress.
  • Preferred antioxidants are vitamin E and its derivatives and vitamin A and its derivatives.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 0.1 to 10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to derive their respective concentrations from the Range from 0.001 to 10 wt .-%, based on the total weight of the formulation to choose.
  • the active ingredients can also be selected very advantageously from the group of lipophilic active ingredients, in particular from the following group:
  • the active ingredient (s) are particularly advantageously selected from the group of NO synthase inhibitors, in particular if the preparations according to the invention for the treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin should serve.
  • the preferred NO synthase inhibitor is nitroarginine.
  • the active ingredient (s) are furthermore advantageously selected from the group which comprises catechins and bile esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile esters of catechins, such as, for example, the leaves of the plant family Theaceae, in particular of the species Camellia sinensis (green tea).
  • catechins and bile esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile esters of catechins, such as, for example, the leaves of the plant family Theaceae, in particular of the species Camellia sinensis (green tea).
  • Their typical ingredients such as polyphenols or Catechins, caffeine, vitamins, sugar, minerals, amino acids, lipids).
  • Catechins are a group of compounds which are to be regarded as hydrogenated flavones or anthocyanidins and derivatives of "catechins” (catechol, 3,3 ', 4', 5,7-flavanpentaol, 2- (3,4-dihydroxyphenyl) -chroman -3,5,7-triol) Also epicatechin ((2R, 3R) -3,3 ', 4', 5,7-flavanpentaol) is an advantageous active substance in the sense of the present invention.
  • Plant extracts containing catechins in particular extracts of green tea, such as. B. extracts from leaves of the plants of the species Camellia spec, especially the teas Camellia sinenis, C. assamica, C. taliensis or C. irrawadiensis and crosses of these with, for example, Camellia japonica.
  • Preferred active substances are also polyphenols or catechins from the group (-) - catechin, (+) - catechin, (-) - catechin gallate, (-) - gallocatechin gallate, (+) - epicatechin, (-) - epicatechin, (-) -Epicatechin gallate, (-) - epigallocatechin, (-) - epigallocatechin gallate.
  • Flavon and its derivatives are advantageous active substances in the sense of the present invention. They are characterized by the following basic structure (substitution positions specified):
  • flavones usually occur in glycosidated form.
  • the flavonoids are preferably selected from the group of substances of the generic structural formula
  • Z to Z 7 are independently selected from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 carbon atoms, and wherein Gly is selected from the group Group of the mono- and oligoglycoside residues.
  • the flavonoids can also be advantageously selected from the group of substances of the generic structural formula where Z ⁇ to Ze are independently selected from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 carbon atoms, and wherein Gly is selected from the Group of the mono- and oligoglycoside residues.
  • Such structures can preferably be selected from the group of substances of the generic structural formula
  • Gly ! , Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
  • Gly 1 ( Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be advantageous
  • pentosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl.
  • Z t to Z 5 are advantageously selected independently of one another from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure door
  • Gly ⁇ Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
  • Gly, Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously, if appropriate. It can also be advantageous according to the invention to use pentosyl residues.
  • flavone glycosides from the group ⁇ -glucosyl rutin, ⁇ -glucosyl myrcetin, ⁇ -glucosyl iso-quercitrin, ⁇ -glucosyl iso-quercetin and ⁇ -glucosyl-quercitrin.
  • ⁇ -glucosylrutin is particularly preferred.
  • naringin aurantiin, naringenin-7-rhamnoglucoside
  • hesperidin S'. ⁇ J-trihydroxy ⁇ '- methoxyflavanon ⁇ -rutinoside, hesperidoside, hesperetin-7-O-rutinoside
  • Rutin S.S ' ⁇ '.
  • the active ingredient (s) from the group of ubiquinones and plastoquinones.
  • Coenzyme Q10 which is characterized by the following structural formula, is particularly advantageous:
  • Creatine and / or creatine derivatives, phsophocreatine are also preferred active substances in the sense of the present invention. Creatine is characterized by the following structure:
  • Preferred derivatives are creatine phosphate and creatine sulfate, creatine acetate, creatine ascorbate and the derivatives esterified on the carboxyl group with mono- or polyfunctional alcohols.
  • acyl-carnitine which is selected from the group of substances of the following general structural formula OW
  • R is selected from the group of branched and unbranched alkyl radicals having up to 10 carbon atoms are advantageous active substances in the sense of the present invention.
  • Propionylcarnitine and in particular acetylcarnitine are preferred.
  • Both entantiomers (D- and L-form) can be used advantageously for the purposes of the present invention. It can also be advantageous to use any mixture of enantiomers, for example a racemate of D and L form.
  • active ingredients are sericoside, pyridoxol, aminoguadin, phytochelatin, isoflavones (genistein, daidzein, daidzin, glycitin), niacin, tyrosine sulfate, dioic acid, adenosine, pyridoxine, arginine, vitamin K, biotin and flavorings.
  • the list of active substances or combinations of active substances mentioned which can be used in the preparations according to the invention is of course not intended to be limiting.
  • the active ingredients can be used individually or in any combination with one another.
  • Active substances can be contained in the preparations in the amounts of 0.0001-25% by weight, preferably 0.001-20% by weight, in particular 0.01-10% by weight, in each case based on the total weight of the preparations.
  • hydrophilic active substances are of course also favored according to the invention
  • a further advantage of the preparations according to the invention is that the high number of very finely divided droplets makes especially oil-soluble or lipophilic active substances biologically available with particularly great effectiveness.
  • Aqueous cosmetic cleaning agents according to the invention or water-free or anhydrous cleaning agent concentrates intended for aqueous cleaning can contain cationic, anionic, nonionic and / or amphoteric surfactants, for example conventional soaps, for example sodium fatty acid salts, alkyl sulfates, alkyl ether sulfates, alkane and alkylbenzenesulfonates, sulfoacetates, sulfobetaine Sarcosinates, amidosulfobetanes, sulfosuccinates, sulfosuccinic acid half-esters, alkyl ether carboxylates, protein fatty acid condensates, alkyl betanes and amidobetaones, fatty acid alkano
  • conventional soaps for example sodium fatty acid salts, alkyl sulfates, alkyl ether sulfates, alkane and alkylbenzenesulfonates, sulf
  • Cosmetic preparations which are cosmetic cleaning preparations for the skin, can be in liquid or semi-solid form, for example as gels. They preferably contain at least one anionic, cationic, non-ionic or amphoteric surface-active substance or mixtures thereof, optionally electrolytes and auxiliaries, as are usually used therefor.
  • the surface-active substance can preferably be present in the cleaning preparations in a concentration of between 1 and 30% by weight, based on the total weight of the preparations.
  • Cosmetic preparations which are a shampooing agent preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof, optionally electrolytes and auxiliaries, as are usually used therefor.
  • the 'surface active agent loading can vorzugt present in a concentration between 1 and 50 wt .-% in the cleansing preparations, based on the total weight of the preparations. Cetyltrimethylammonium salts, for example, are advantageous to use.
  • the preparations according to the invention for cleaning the hair or skin contain water and, if appropriate, the additives customary in cosmetics, for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts , Vitamins, active ingredients and the like.
  • the preparations according to the invention surprisingly have very good foaming, high cleansing power and have a highly regenerative effect on the general skin condition.
  • the preparations according to the invention have a skin-smoothing effect, reduce the feeling of dryness of the skin and make the skin supple.
  • preparations according to the invention are to be used for hair care, they can contain the usual constituents, usually for example film-forming polymers.
  • film formers are preferably those which are selected from the group of substances which, according to the INCI nomenclature (International Nomenclature Cosmetic
  • Polyquaternium-2 (Chemical Abstracts No. 63451-27-4, e.g. Mirapol® A-15)
  • Polyquaternium-5 (copolymer of the acrylamide and the ß-methacryloxyethyl-trimethylammonium methosulfate, CAS No. 26006-22-4)
  • Polyquaternium-6 (homopolymer of N, N-dimethyl-N-2-propenyl-2-propen-1-aminium chloride, CAS No. 26062-79-3, e.g. Merquat® 100
  • Copolymer e.g. Gafquat® HS-100
  • Polyquaternium-29 e.g. Lexquat® CH Polyquaternium-31 CAS no. 136505-02-7, e.g. Hypan® QT 100 Polyquaternium-32,, N-trimethyl-2 - [(2-methyl-1-oxo-2-propenyl) oxy] -Ethanami- nium chloride, polymer with 2-propenamide, CAS no. 35429-19-7 Polyquaternium-37 CAS-No. 26161-33-1 cetyl trimethyl ammonium salts such as CTAB, CTAC.
  • Preparations according to the invention for hair care advantageously contain 0.01-5% by weight of one or more film formers, preferably 0.1-3% by weight, in particular 0.2-2% by weight, in each case based on the total weight of the preparations.
  • Such embodiments of the preparations according to the invention care for hair damaged or damaged by environmental influences or prevent such environmental influences.
  • the preparations according to the invention give the hairstyle loose fullness and firmness without being tacky.
  • the preparations according to the invention can be used, for example, as a skin protection emulsion, cleansing milk, sunscreen lotion, nutrient lotion, day or night emulsion, etc.
  • the preparations according to the invention also make an excellent contribution to smoothing the skin, in particular if they are provided with one or more substances which promote smoothing of the skin. It may be possible and advantageous to use the preparations according to the invention as the basis for pharmaceutical formulations. Mutatis mutandis, corresponding requirements apply to the formulation of medical preparations.
  • the transitions between pure cosmetics and pure pharmaceuticals are fluid.
  • all classes of active substances are in principle geeginet as pharmaceutical active substances, lipophilic active substances being preferred. Examples are: antihistamines, anti-inflammatory drugs, antibiotics, antifungals, active substances that promote blood circulation, keratolytics, hormones, steroids, vitamins, etc.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, virucides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, anti-inflammatory substances, medicines, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents.
  • cosmetic auxiliaries e.g. Preservatives, bactericides, virucides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, anti-inflammatory substances, medicines, fats, oils, waxes or other usual components
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids, alcohols, diols or low C number polyols, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or - monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products.
  • esters of fatty acids with alcohols of low C number e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids, alcohols, dio
  • Phosphatidylcholine (Phospholipon 90, Rhone-Poulenc / Nattermann) was used as lecithin in the examples.
  • perfume fragrances perfume atomizers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de production d'émulsions de type huile dans eau contenant des phospholipides, présentant une faible viscosité et qui sont en particulier pulvérisables. Ces émulsions contiennent une phase aqueuse et une phase huileuse qui sont essentiellement constituées de composants peu volatils et comprennent au moins un phospholipide et au moins un émulsifiant huile dans eau et éventuellement au moins émulsifiant E/H. Selon ledit procédé de production, une partie de la phase aqueuse et ses composants est ajoutée à la phase huileuse et ses composants, en particulier le phospholipide et l'émulsifiant H/E et éventuellement l'émulsifiant E/H. Ces phases sont mélangées et l'on obtient un gel qui est transformé en une émulsion H/E peu visqueuse par addition supplémentaire de phase aqueuse. Si souhaité, les phases peuvent contenir d'autres agents auxiliaires, additifs et/ou substances actives.
PCT/EP2003/002983 2002-03-28 2003-03-21 Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides WO2003082222A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03745267A EP1492490A2 (fr) 2002-03-28 2003-03-21 Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides
US10/953,586 US20050124705A1 (en) 2002-03-28 2004-09-28 Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002113955 DE10213955A1 (de) 2002-03-28 2002-03-28 Kosmetische oder pharmazeutische phospholipidhaltige, niedrigviskose (versprühbare) O/W-Emulsionen
DE10213955.5 2002-03-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/953,586 Continuation US20050124705A1 (en) 2002-03-28 2004-09-28 Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids

Publications (2)

Publication Number Publication Date
WO2003082222A2 true WO2003082222A2 (fr) 2003-10-09
WO2003082222A3 WO2003082222A3 (fr) 2004-02-26

Family

ID=27816029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/002983 WO2003082222A2 (fr) 2002-03-28 2003-03-21 Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides

Country Status (3)

Country Link
EP (1) EP1492490A2 (fr)
DE (1) DE10213955A1 (fr)
WO (1) WO2003082222A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
EP2428200A2 (fr) 2006-11-29 2012-03-14 Malvern Cosmeceutics Limited Nouvelles compositions
CN112512484A (zh) * 2018-08-08 2021-03-16 苏比品牌公司 化妆品基体组合物和相关的化妆品组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004027329A1 (de) * 2004-06-03 2005-12-29 Beiersdorf Ag Kosmetische Zubereitung mit ethoxylierten Glycerinen und ethoxylierten Glycerin-Fettsäureestern
DE102004047285A1 (de) * 2004-09-27 2006-04-20 Beiersdorf Ag Organische Mikropigmente enthaltende kosmetische Lichtschutzemulsion
DE102010034389B4 (de) 2010-08-13 2018-03-22 Beiersdorf Ag Stabilisierte W/O-Emulsionen
DE202010011395U1 (de) 2010-08-13 2010-11-11 Beiersdorf Ag Stabilisierte W/O-Emulsionen
WO2012167900A2 (fr) 2011-06-07 2012-12-13 Beiersdorf Ag Compositions cosmétiques ou dermatologiques sous forme d'émulsions et ayant une libération de parfum améliorée
DE102011077045A1 (de) 2011-06-07 2012-12-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit verbesserter mikrobiologischer Stabilität
DE102011077028A1 (de) 2011-06-07 2012-12-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit verbesserten rheologischen Eigenschaften
DE102011077037A1 (de) 2011-06-07 2012-12-13 Beiersdorf Ag Kosmetische oder dermatologische Lichtschutzzubereitung mit verbesserter Wasserfestigkeit
DE102011077031A1 (de) 2011-06-07 2012-12-13 Beiersdorf Ag Fettalkohol-freie kosmetische oder dermatologische Emulsionszubereitungen
WO2012167905A2 (fr) 2011-06-07 2012-12-13 Beiersdorf Ag Compositions cosmétiques ou dermatologiques exemptes de polyéthylène glycol
DE102011077018A1 (de) * 2011-06-07 2012-12-13 Beiersdorf Ag Polyethylenglykol-freie kosmetische oder dermatologische Zubereitungen
WO2013079621A1 (fr) 2011-11-29 2013-06-06 Art-Fi Composition simulant les propriétés diélectriques d'un corps humain et utilisation de celui-ci pour une mesure de sar
DE102014220449A1 (de) * 2014-10-09 2016-04-14 Beiersdorf Ag Kosmetisches Spray
CN107522735A (zh) * 2017-09-21 2017-12-29 安徽元创科技有限公司 以溶剂法生产低粘度磷脂产品的方法
CN109517190A (zh) * 2018-11-23 2019-03-26 中国石油集团渤海钻探工程有限公司 用于乳化中低粘度二甲基硅油的复合乳化剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100448A1 (fr) * 1982-07-09 1984-02-15 A. Nattermann & Cie. GmbH Formulations liquides d'agent actif et leur emploi dans la préparation de microémulsions
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
WO1997009964A1 (fr) * 1995-09-12 1997-03-20 Astra Aktiebolag Microemulsions servant de vehicule en vue de l'administration de composes actifs
WO1997030695A1 (fr) * 1996-02-23 1997-08-28 Lds Technologies, Inc. Compositions d'apport medicamenteux convenant a l'injection intraveineuse
WO2000037042A1 (fr) * 1998-12-22 2000-06-29 Beiersdorf Ag Gels contenant de la lecithine, ou micro-emulsions huile dans l'eau, contenant de la lecithine, de basse viscosite, a usage cosmetique ou pharmaceutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100448A1 (fr) * 1982-07-09 1984-02-15 A. Nattermann & Cie. GmbH Formulations liquides d'agent actif et leur emploi dans la préparation de microémulsions
EP0760237A1 (fr) * 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
WO1997009964A1 (fr) * 1995-09-12 1997-03-20 Astra Aktiebolag Microemulsions servant de vehicule en vue de l'administration de composes actifs
WO1997030695A1 (fr) * 1996-02-23 1997-08-28 Lds Technologies, Inc. Compositions d'apport medicamenteux convenant a l'injection intraveineuse
WO2000037042A1 (fr) * 1998-12-22 2000-06-29 Beiersdorf Ag Gels contenant de la lecithine, ou micro-emulsions huile dans l'eau, contenant de la lecithine, de basse viscosite, a usage cosmetique ou pharmaceutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUMIYOSHI ISHII ET AL.: "Effect of phospholipid emulsifiers on physical properties of intravenous fat emulsions and/or carrier emulsions" J.PHARM. PHARMACOL., Bd. 42, 1990, Seiten 513-515, XP009018382 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
EP2428200A2 (fr) 2006-11-29 2012-03-14 Malvern Cosmeceutics Limited Nouvelles compositions
CN112512484A (zh) * 2018-08-08 2021-03-16 苏比品牌公司 化妆品基体组合物和相关的化妆品组合物

Also Published As

Publication number Publication date
EP1492490A2 (fr) 2005-01-05
WO2003082222A3 (fr) 2004-02-26
DE10213955A1 (de) 2003-10-09

Similar Documents

Publication Publication Date Title
EP1450760B1 (fr) Preparations cosmetiques et dermatologiques pour apaiser les demangeaisons
US20050142153A1 (en) Crosslinked cosmetic or pharmaceutical phospholipid-containing gels and emulsions based on ethylene oxide-containing or propylene oxide-containing emulsifiers
US20050124705A1 (en) Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids
WO2003082222A2 (fr) Emulsions h/e cosmetiques ou pharmaceutiques peu visqueuses (pulverisables) contenant des phospholipides
EP1549281B1 (fr) Emulsions eau-huile pulverisables sous forme d'aerosol
DE10059584A1 (de) Kosmetische oder dermatologische getränkte Tücher
EP0814753A2 (fr) Gels cosmetiques ou dermatologiques a base de microemulsions
DE202006001274U1 (de) Duftende kosmetische Zubereitung
DE10154627A1 (de) Kosmetische oder dermatologische getränkte Tücher
US7811594B2 (en) Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE102008059445A1 (de) Schäumende Emulsionen mit Emulgatorkombination
DE10129973A1 (de) Kosmetische oder dermatologische getränkte Tücher
EP1993507A1 (fr) Préparations cosmétiques comprenant un additif tiré du baobab
DE10154547A1 (de) Dünnflüssige, sprühbare W/O Emulsionen
EP1269978B1 (fr) Utilisation de dérivés de la bis-resorcinyl triazine dans des préparations cosmétiques ou dermatologiques
DE10344888A1 (de) Kosmetische oder pharmazeutische Emulsionen auf der Basis von vernetzten Öltröpfchen
EP1013262A2 (fr) Emulsions H/E cosmetiques et dermatologiques contenant de nitrure de bore
EP1557153A1 (fr) Emulsions eau-dans-huile à faible viscosité sans emulsifiants huile-dans-eau.
EP1555017A1 (fr) Emulsions eau-dans-huile à faible viscosité
DE10213956A1 (de) Kosmetische oder pharmazeutische Emulsionen auf der Basis von vernetzten Öltröpfchen
DE10163853B4 (de) Kosmetische und/oder dermatologische W/O-Emulsionen, Verfahren zur Stabilisierung, sowie deren Verwendung
DE10131796A1 (de) Verwendung von Cardiolipin in kosmetischen oder dermatologischen Zubereitungen
DE10148301A1 (de) Kosmetische und dermatologische Stifte
DE102005048779A1 (de) Kosmetische Formulierungen zur Verbesserung der Hautbarrierefunktion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003745267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10953586

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003745267

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWR Wipo information: refused in national office

Ref document number: 2003745267

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003745267

Country of ref document: EP